戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  or the combination of anastrozole 1 mg with pictilisib 260 mg once per day (n = 49).
2 chical randomisation algorithm to daily oral pictilisib (340 mg in part 1 and 260 mg in part 2) or pl
3 14, we randomly allocated 61 patients to the pictilisib (41 [67%]) or placebo (20 [33%]) group.
4 atients were analysed according to presence (pictilisib 6.5 months [95% CI 3.7-9.8] vs placebo 5.1 mo
5 median progression-free survival between the pictilisib (6.6 months [95% CI 3.9-9.8]) and placebo (5.
6 3, we randomly allocated 168 patients to the pictilisib (89 [53%]) or placebo (79 [47%]) group.
7      We identified a class I PI3K inhibitor, pictilisib and p21 activated kinase (PAK) inhibitor, PF-
8 mutations were not predictive of response to pictilisib, but there was significant interaction betwee
9 athways by the small-molecule PI3K inhibitor pictilisib (GDC-0941) and the MEK inhibitor cobimetinib
10 y assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects
11 s occurred in 54 (61%) of 89 patients in the pictilisib group and 22 (28%) of 79 in the placebo group
12 s occurred in 15 (36%) of 42 patients in the pictilisib group and seven (37%) of 19 patients in the p
13  significant Ki-67 response was observed for pictilisib in luminal A tumors (1.01; P = .98).
14                  No further investigation of pictilisib in this setting is ongoing.
15                                              Pictilisib is an oral inhibitor of multiple PI3K isoform
16 bitors with greater selectivity than that of pictilisib might be needed to improve tolerability and p
17 orally bioavailable class I PI3K inhibitors, pictilisib or buparlisib, display elevated CMA activity,
18 of selective responses to the PI3K inhibitor pictilisib, the fatty acid synthase inhibitor GSK2194069
19                                       Adding pictilisib to anastrozole significantly increases suppre
20 of this study is to establish if addition of pictilisib to fulvestrant can improve progression-free s
21                         Although addition of pictilisib to fulvestrant did not significantly improve
22         19 serious adverse events related to pictilisib treatment were reported in 14 (16%) of 89 pat
23       Four serious adverse events related to pictilisib treatment were reported in two (5%) of 42 pat
24 improve progression-free survival, dosing of pictilisib was limited by toxicity, potentially limiting